Copyright
©The Author(s) 2017.
World J Nephrol. Jul 6, 2017; 6(4): 188-200
Published online Jul 6, 2017. doi: 10.5527/wjn.v6.i4.188
Published online Jul 6, 2017. doi: 10.5527/wjn.v6.i4.188
Figure 3 Liver morphology of tesevatinib-treated BPK mice.
Histological analysis of hematoxylin stained BPK livers reveals a marked decrease in the biliary ductal ectasia (arrow) following treatment with TSV at 7.5 mg/kg per day (B) (arrow) and 15 mg/kg per day (C) when compared to untreated BPK livers (A) (Treatment interval: PN4-PN21).
- Citation: Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 2017; 6(4): 188-200
- URL: https://www.wjgnet.com/2220-6124/full/v6/i4/188.htm
- DOI: https://dx.doi.org/10.5527/wjn.v6.i4.188